ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  HIV-1 drug mutations in children from northern Tanzania.
 PMID: 24729604       2014       The Journal of antimicrobial chemotherapy
Table: V106I


  Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
 PMID: 24746180       2014       Journal of the International AIDS Society
Introduction: It must be noted, that analysis of the ECHO and THRIVE clinical data indicated that the presence of V90I, V106I, V179I and V189I was not associated with virological failure; therefore, these mutations are not likely to be associated with RPV resistance in vivo .


  Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
 PMID: 25166019       2014       PloS one
Result: Regarding the NNRTI mutations, V90L, K101E, K103N/S, V106I/M, V1791L were observed in both patients groups.


  Minority drug-resistant HIV-1 variants in treatment naive East-African and Caucasian patients detected by allele-specific real-time PCR.
 PMID: 25333961       2014       PloS one
Table: V106I


  Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.
 PMID: 25397500       2014       Journal of the International AIDS Society
Table: V106I


  HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China.
 PMID: 25510523       2014       BMC infectious diseases
Abstract: Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year.
Result: Among subtype B, 54.5% (12/22) had TDR-associated mutations, A71T/V and V106I being the most frequent.
Table: V106I


  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
 PMID: 25575025       2014       Retrovirology
Table: V106I


  Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
 PMID: 22951490       2013       Antiviral therapy
Abstract: The presence of allowed NNRTI RAMs was associated with comparable response rates to the overall population (RPV 84.3% versus EFV 82.3%, intent-to-treat time-to-loss-of-virological-response): V90I (82.4% and 100% for RPV and EFV, respectively), V106I (85.7% and 93.3%), V179I (87.7% and 94.0%) and V189I (100.0% and 88.9%).


  HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection.
 PMID: 23161095       2013       Journal of medical virology
Abstract: DRAMs to NNRTIs were V106I (7%), V179D (4.2%), V179T (1.8%), E138A (1.5%), V90I (1.2%), K103N (0.9%), Y181C (0.9%), and P225H (0.3%).


  Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.
 PMID: 23296905       2013       Medical microbiology and immunology
Abstract: In these patients, the nucleoside reverse transcriptase inhibitor (NRTI)-associated resistance mutations M41L, T215C, V75I, T69N, the non-NRTI associated mutations V106I, E138A, K103N and the protease inhibitor associated mutations Q58E and V82I were detected.



Browser Board

 Co-occurred Entities




   Filtrator